GeneDx Holdings Corp reports results for the quarter ended September 30 - Earnings Summary

• GeneDx Holdings Corp WGS.OQ reported quarterly adjusted earnings of 49 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 4 cents. The mean expectation of nine analysts for the quarter was for earnings of 42 cents per share. Wall Street expected results to range from 28 cents to 55 cents per share.

• Revenue rose 51.9% to $116.74 million from a year ago; analysts expected $104.67 million.

• GeneDx Holdings Corp's reported EPS for the quarter was a loss of 27 cents​.

• The company reported a quarterly loss of $7.64 million.

• GeneDx Holdings Corp shares had risen by 21.3% this quarter and gained 70.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 22.2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

• Wall Street's median 12-month price target for GeneDx Holdings Corp is $125.00, about 4.5% below its last closing price of $130.66

This summary was machine generated from LSEG data October 28 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)